Figure 2.

Discordant response between bone and visceral metastases on fluorodeoxyglucose (FDG)-positron emission tomography (PET) exams performed before (left) and after (right) 3 months of treatment with gemcitabine-trastuzumab. Baseline FDG-PET shows hypermetabolic activity in bilateral and multifocal breast tumors, lymph node involvement of right axilla, and bone metastases. After treatment, PET demonstrated an heterogeneous metabolic response with coexistence of responding (left breast, axillary nodes) and nonresponding metastatic bone lesions (red arrows, moderate increased in focal uptake of the two bone lesions).